Immucor, Inc. (NASDAQ:BLUD) will release the second quarter earnings for 2010 on Wednesday, January 6. The company will host a conference call the following morning, Thursday, January 7, at 8:30 am ET to review the financial results. Interested parties may join the call by dialing 1.888.324.9321 and providing the pass code BLUD.
MicroCap Insider is a web-based financial portal.
Sign Up for our Free Stock Newsletter
MicroCap Insider publishes a free penny stock newsletter providing stock alerts on companies positioned to deliver high-yield gains to investors.
A telephone replay will be available for those unable to join the call at the scheduled time. To listen to the replay, dial 1.866.475.1458 and enter the pass code 6533. A webcast will also be available on the company’s Investor Relations page of its website, http://www.immucor.com/.
Immucor, Inc. (Immucor) develops, manufactures and sells a line of reagents and automated systems that detect and identify certain properties of the cell and serum components of human blood for the purpose of blood transfusion. The Company has manufacturing facilities in the United States and Canada and sells its products through its direct sales network in the United States, Canada, Western Europe and Japan, as well as through third-party distributors in other markets. As of May 31, 2009, the Company had received orders for a total of 603 Echo instruments worldwide, including 121 orders in Europe including distributors, 470 orders in the United States and Canada, and 12 orders in Japan. On August 4, 2008, Immucor acquired BioArray Solutions Ltd.
Sign Up for FREE. Investors interested in receiving small cap stock alerts through the penny stock newsletter published by MicroCap Insider can sign up for free by visiting our website.
About Us
MicroCap Insider is a leading penny stock web site with extensive experience in the OTC market, providing top stock picks, investing tips and exclusive research on small cap stocks on the verge of producing large financial gains.
Please click here to read the full disclaimer.
